Summer 2025
By Bethany Herrema
PHASE ONE gave $273,768 to support Glenn Hanna, MD, who is leading a study to investigate a potential therapeutic target for a subgroup of adenoid cystic carcinoma (ACC) patients. This rare disease usually arises in the salivary glands, and there are currently no approved systemic therapies for advanced or metastatic ACC.